阿托伐他汀并曲美他嗪对冠心病患者血脂、炎性因子及心功能的疗效分析

Analysis of the efficacy of atorvastatin combined with trimetazidine on blood lipids,inflammatory factors and cardiac function in patients with coronary heart disease

目的分析冠心病患者应用阿托伐他汀并曲美他嗪治疗对炎性因子、血脂、心功能的影响。方法64例冠心病患者,随机分为对照组和观察组,每组32例。对照组采用曲美他嗪治疗,观察组在对照组基础上采用阿托伐他汀治疗。比较两组患者的治疗效果及治疗前后炎性因子、血脂指标、心功能指标。结果观察组患者治疗总有效率为93.75%,高于对照组的71.88%,差异具有统计学意义(P<0.05)。治疗后,观察组患者高密度脂蛋白胆固醇(1.48±0.32)mmol/L高于对照组的(1.31±0.21)mmol/L,低密度脂蛋白胆固醇(1.88±0.35)mmol/L、甘油三酯(1.42±0.67)mmol/L、总胆固醇(4.35±0.63)mmol/L低于对照组的(2.32±0.57)、(2.06±0.72)、(5.16±0.64)mmol/L,差异具有统计学意义(P<0.05)。治疗后,观察组患者基质金属蛋白酶-9为(30.57±8.55)ng/ml、肿瘤坏死因子-α为(101.53±22.05)pg/ml、超敏C反应蛋白为(2.51±0.84)mg/L,均低于对照组的(41.56±11.32)ng/ml、(180.57±31.27)pg/ml、(4.22±0.33)mg/L,差异具有统计学意义(P<0.05)。治疗后,观察组患者左心室射血分数(48.59±5.26)%高于对照组的(40.24±6.23)%,左心室舒张末期内径(48.55±4.31)mm短于对照组的(58.51±5.22)mm,左室后壁厚度(9.01±1.18)mm低于对照组的(11.07±1.04)mm,差异具有统计学意义(P<0.05)。结论阿托伐他汀并曲美他嗪对冠心病患者血脂、炎性因子及心功能的疗效显著。

Objective To analyze the effect atorvastatin combined with trimetazidine on blood lipids,inflammatory factors and cardiac function in patients with coronary heart disease.Methods A total of 64 patients with coronary heart disease were randomly divided into control group and observation group,with 32 cases in each group.The control group was treated with trimetazidine,and the observation group was treated with atorvastatin based on the control group.The therapeutic effect,and inflammatory factors,blood lipid indexes,heart function indexes before and after treatment were compared between the two groups.Results The total effective rate in the observation group was 93.75%,which was higher than 71.88%in the control group,and the difference was statistically significant(P<0.05).After treatment,the high-density lipoprotein cholesterol(1.48±0.32)mmol/L of the observation group was higher than(1.31±0.21)mmol/L of the control group,and the low-density lipoprotein cholesterol(1.88±0.35)mmol/L,triglyceride(1.42±0.67)mmol/L,and total cholesterol(4.35±0.63)mmol/L were lower than(2.32±0.57),(2.06±0.72)and(5.16±0.64)mmol/L of the control group.All the difference was statistically significant(P<0.05).After treatment,the levels of matrix metalloproteinase-9,tumor necrosis factor-αand high-sensitivity C-reactive protein in the observation group were(30.57±8.55)ng/ml,(101.53±22.05)pg/ml and(2.51±0.84)mg/L,which were lower than(41.56±11.32)ng/ml,(180.57±31.27)pg/ml and(4.22±0.33)mg/L in the control group,and the difference was statistically significant(P<0.05).After treatment,the left ventricular ejection fraction(48.59±5.26)%of the observation group was higher than(40.24±6.23)%of the control group,the left ventricular end diastolic diameter(48.55±4.31)mm was shorter than(58.51±5.22)mm of the control group,and the left ventricular posterior wall thickness(9.01±1.18)mm was lower than(11.07±1.04)mm of the control group.All the difference was statistically significant(P<0.05).Conclusion Combination of atorvastatin and trimetazidine has significant efficacy on blood lipid,inflammatory factors and cardiac function in patients with coronary heart disease.